News
Athersys Partner HEALIOS K.K. Announces Positive Topline Results of MultiStem for Acute Respiratory Distress Syndrome in the ONE-BRIDGE Study Athersys to continue to provide close support to ...
InflaRx receives positive CHMP opinion for SARS-CoV-2-induced acute respiratory distress treatment Nov. 15, 2024 9:05 AM ET InflaRx N.V. (IFRX) Stock By: Nilanjana Basu, SA News Editor Play (<1min) ...
Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, can present with a spectrum of clinical manifestations – ranging from mild infection of the upper respiratory tract to severe ...
“Acute respiratory distress syndrome is triggered by a variety of etiologic agents. Currently, there are no FDA-approved drugs to treat ARDS because of which the mortality rate is close to 40% ...
The reason behind acute respiratory distress syndrome development in some patients suffering with severe respiratory illness and not others is unknown, but recent research suggests a possible ...
Acute respiratory distress syndrome, also known as ARDS, is a common killer among critically ill patients hospitalized with COVID-19. But even if they survive, it’s a long road to recovery.
Metabolic Syndrome and Acute Respiratory Distress Syndrome in Hospitalized Patients With COVID-19. JAMA Network Open, 2021; 4 (12): e2140568 DOI: 10.1001/jamanetworkopen.2021.40568 ...
Severe acute respiratory syndrome (SARS) is a respiratory disease first reported in China in 2002. A coronavirus caused the SARS outbreak, which starts with body aches and mild respiratory symptoms.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results